Nabriva Therapeutics AG’s (NBRV) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Nabriva Therapeutics AG (NASDAQ:NBRV) in a report released on Monday. The firm currently has a $18.00 price objective on the biotechnology company’s stock, up from their previous price objective of $16.00.
NBRV has been the topic of a number of other research reports. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics AG and gave the stock a buy rating in a research note on Monday, June 5th. Wedbush reiterated an outperform rating and issued a $13.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. ValuEngine upgraded shares of Nabriva Therapeutics AG from a sell rating to a hold rating in a research note on Saturday, June 24th. SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a research note on Friday, August 25th. They issued a buy rating and a $20.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a sell rating to a hold rating and set a $12.00 price objective on the stock in a research note on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Nabriva Therapeutics AG has a consensus rating of Buy and an average target price of $16.25.
Nabriva Therapeutics AG (NASDAQ NBRV) opened at 9.30 on Monday. The company has a 50-day moving average price of $9.92 and a 200 day moving average price of $10.40. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75. The stock’s market cap is $249.59 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. Equities analysts expect that Nabriva Therapeutics AG will post ($2.34) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/nabriva-therapeutics-ags-nbrv-buy-rating-reiterated-at-hc-wainwright/1533014.html.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $10.94, for a total transaction of $143,609.38. Following the sale, the insider now directly owns 2,583,229 shares of the company’s stock, valued at $28,260,525.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 241,923 shares of company stock worth $2,567,274 over the last three months. 2.75% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors increased its stake in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares during the period. Royal Bank of Canada increased its stake in shares of Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after buying an additional 8,650 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Nabriva Therapeutics AG during the fourth quarter worth about $103,000. Almanack Investment Partners LLC. purchased a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $1,870,000. Finally, Wellington Management Group LLP increased its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the period. 68.56% of the stock is currently owned by hedge funds and other institutional investors.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.